Pharmaceuticals - Generic / Specialty

Mylan Inc Reaffirms FY 2013 EPS Guidance

Mylan Inc announced that it is its reaffirming fiscal 2013 adjusted diluted EPS guidance range of $2.75-$2.95 per share. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $2.87 for fiscal 2013.

7:30am EDT

Repligen Corp Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EBIT Guidance; Lowers FY 2013 Net Income Guidance

Repligen Corp announced that total revenue for fiscal 2013 is expected to be $65-$67 million, an increase from its prior guidance of $63-$65 million. This projection includes the receipt of royalties from Bristol-Myers Squibb on its U.S. sales of Orencia which the Company will no longer receive...

7:30am EDT

AMAG Pharmaceuticals Inc Raises FY 2013 Revenue Guidance

AMAG Pharmaceuticals Inc updated its annual financial guidance for fiscal 2013. AMAG now expects to achieve the following in fiscal 2013: Total revenues of between $77 million and $80 million, including: Feraheme U.S. net product sales of between $67 million and $70 million, revised upward from the...

7:30am EDT

Auxilium Pharmaceuticals Inc Narrows FY 2013 Revenue Guidance TO A Range In Line WIth Analysts Estimates

Auxilium Pharmaceuticals Inc updated its fiscal 2013 Guidance and it expects total revenues of $363 million to $405 million . According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $373 million for fiscal 2013.

7:02am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: GUOTAI JUNAN Securities Co.Ltd
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.